Regenerative Medicine · Cyprus

PRGF (PRP) Injection

Autologous infiltration of Plasma Rich in Growth Factors (PRGF), prepared from the patient's own blood with the BTI Endoret® system, for mild-to-moderate osteoarthritis, chronic tendinopathy, and soft-tissue injury. Private-pay regenerative procedure in Cyprus.

timer3 min read translateAvailable in EN

Quick Answers

What is the difference between PRGF and PRP?

PRGF (Plasma Rich in Growth Factors) is the standardised, leukocyte-free autologous protocol developed by BTI Biotechnology Institute. Generic "PRP" varies in preparation, platelet concentration, leukocyte content, and activator.

Is PRGF covered by GESY in Cyprus?

No. Endoret® (PRGF) is a private-pay regenerative procedure in Cyprus.

What does the published evidence show?

The strongest evidence is in mild-to-moderate knee osteoarthritis and chronic rotator cuff tendinopathy. In a 176-patient multicentre double-blind randomised controlled trial, PRGF-Endoret produced a response rate 14.1 percentage points higher than hyaluronic acid at 24 weeks (Sánchez 2012, PubMed 22840987).

How many sessions are needed?

Typically 1 to 3 sessions depending on indication and clinical response. The published knee osteoarthritis protocol uses 3 weekly injections per cycle (Sánchez 2012, Vaquerizo 2013).

What is PRGF (PRP) Injection?

Also known as: Plasma Rich in Growth Factors injection, PRP injection, autologous platelet-rich plasma, leukocyte-poor PRP, intra-articular platelet injection, intratendinous PRP, growth factor injection, regenerative orthobiologics, autologous platelet therapy

PRGF (Plasma Rich in Growth Factors) is the standardised, leukocyte-free autologous platelet protocol developed by BTI Biotechnology Institute (Vitoria-Gasteiz, Spain). Generic "PRP" varies in preparation, platelet concentration, leukocyte content, and activator. PRGF differs in protocol, characterisation, and regulatory file: a closed, single-step centrifugation that yields two plasma fractions (F1 at 1 to 1.5x platelet concentration, F2 at 2 to 3x and leukocyte-free), activated with calcium chloride immediately before infiltration.

In Cyprus, PRGF is administered using the Endoret® system, distributed exclusively by OrganoGEN. A small autologous blood draw is processed on-site, activated, and infiltrated at the target joint, tendon, or soft-tissue lesion. Typical clinic visit is under 60 minutes end-to-end. The technology has been used clinically since 1999, the first PRP-class biologic published for musculoskeletal indications.

📋 Procedure at a Glance

Source
Autologous (own blood)
System
Endoret® (BTI, Spain)
Visit time
Under 60 min end-to-end
Anaesthesia
Local infiltration if required
Sessions
1–3 per indication
GESY
Private-pay (regenerative tier)

Am I a candidate?

Good candidates

  • Mild-to-moderate knee osteoarthritis (Kellgren-Lawrence grade 1 to 3)
  • Mild-to-moderate hip or shoulder osteoarthritis
  • Chronic tendinopathy (rotator cuff, lateral epicondyle, patellar, achilles, plantar fascia)
  • Soft-tissue injury and post-surgical augmentation
  • Patients seeking a non-surgical regenerative option, or seeking to delay arthroplasty

Patients in whom another option may be preferred

  • Active local or systemic infection
  • Active malignancy at or near the target site
  • Severe haematological disorder or coagulopathy
  • End-stage osteoarthritis (Kellgren-Lawrence 4) where joint replacement is the appropriate option
  • Patient-specific contraindications to autologous blood handling

GESY coverage & out-of-pocket cost

This is a private-pay procedure. Endoret® (PRGF) sits in the regenerative tier in Cyprus and is not covered by GESY. GESY covers standard orthopaedic surgical procedures and conventional injectables. Autologous biologics are private-pay. OrganoGEN provides clinic quotations on request. Request a quote.

Devices used in this procedure

Endoret® PRGF - Plasma Rich in Growth FactorsRegenerative Medicine · Plasma Rich in Growth Factorschevron_right

Where to have PRGF (PRP) Injection in Cyprus

OrganoGEN supplies GESY-contracted hospitals across the island. Contact us for the current list of participating surgeons in:

LimassolNicosiaLarnacaPaphosFamagustaAll clinics

Talk to a surgeon in Cyprus

OrganoGEN can connect you with a participating GESY-contracted surgeon for a consultation.

Request Referral

Frequently asked questions

What is the difference between PRGF and PRP?
PRGF (Plasma Rich in Growth Factors) is the standardised, leukocyte-free autologous protocol developed by BTI Biotechnology Institute. Generic "PRP" varies in preparation, platelet concentration, leukocyte content, and activator. PRGF is prepared with a closed single-step centrifugation that yields two plasma fractions (F1 at 1 to 1.5x platelet concentration, F2 at 2 to 3x and leukocyte-free), activated with calcium chloride at the point of care. PRGF is classified as a pure, leukocyte-free P-PRP in the standard PRP taxonomy (Dohan Ehrenfest 2009, PubMed 19187989).
Is PRGF covered by GESY in Cyprus?
No. Endoret® (PRGF) is a private-pay regenerative procedure in Cyprus. GESY covers standard orthopaedic procedures and conventional injectables. Autologous biologics sit in the private tier.
What does the published evidence show?
The strongest evidence is in mild-to-moderate knee osteoarthritis and chronic rotator cuff tendinopathy. In a 176-patient multicentre double-blind randomised controlled trial, PRGF-Endoret produced a response rate 14.1 percentage points higher than hyaluronic acid at 24 weeks (Sánchez 2012, PubMed 22840987). In a 96-patient randomised trial, PRGF-Endoret was significantly superior to Durolane hyaluronic acid on WOMAC and Lequesne at 24 and 48 weeks (Vaquerizo 2013, PubMed 24075613). In a 79-patient double-blind trial in chronic rotator cuff tendinopathy, three biweekly PRGF injections were 22.1% superior to corticosteroid on UCLA at 6 months, sustained at 12 months (Vaquerizo 2023, PubMed 36183895). The 2024 ESSKA-ORBIT European consensus regards PRP as a valid first-line injectable option for non-operative management of knee osteoarthritis at Kellgren-Lawrence grades 1 to 3 (Laver et al. 2024).
How many sessions are needed?
Typically 1 to 3 sessions depending on indication and clinical response. The published knee osteoarthritis protocol uses 3 weekly injections per cycle (Sánchez 2012, Vaquerizo 2013). The rotator cuff tendinopathy protocol uses 3 biweekly injections (Vaquerizo 2023). A 90-patient trial in knee osteoarthritis found that two cycles improved stiffness and activities of daily living versus one cycle, without an additional reduction in pain (Vaquerizo 2018, PubMed 28526995).
Is PRGF safe? Are there side effects?
PRGF uses 100% autologous material, the patient's own blood, with no synthetic additives beyond the calcium chloride activator. Reported side effects in published trials are limited to mild local soreness at the injection site for 24 to 48 hours. The 2024 ESSKA-ORBIT consensus rated PRP as having a safer use profile than corticosteroid injection.
Is the Endoret® system regulated?
Yes. The Endoret® closed-technique system carries the European CE health certificate awarded by TÜV-SUD for application to musculoskeletal injuries and is manufactured under ISO 13485:2016 by BTI Biotechnology Institute, Vitoria-Gasteiz, Spain.
Where can I have PRGF injection done in Cyprus?
Through Endoret-trained clinicians in OrganoGEN's network. Contact us for the current list in Limassol, Nicosia, Larnaca, Paphos, and Famagusta.

Information is educational and not a substitute for individual surgical advice. Patient outcomes vary; please consult a qualified surgeon to discuss whether this procedure is right for you.

arrow_back
PRGF / PRP Injection
Regenerative Medicine · Cyprus

PRGF (PRP) Injection

Also known as: Plasma Rich in Growth Factors injection, PRP injection, autologous platelet-rich plasma, leukocyte-poor PRP, intra-articular platelet injection, intratendinous PRP, growth factor injection, regenerative orthobiologics, autologous platelet therapy

Autologous infiltration of Plasma Rich in Growth Factors (PRGF), prepared from the patient's own blood with the BTI Endoret® system, for mild-to-moderate osteoarthritis, chronic tendinopathy, and soft-tissue injury. Private-pay regenerative procedure in Cyprus.

schedule<60 min visithealingOutpatientfavoriteAutologous

Quick Answers

SourceAutologous (own blood)
SystemEndoret® (BTI, Spain)
Visit timeUnder 60 min end-to-end
AnaesthesiaLocal infiltration if required
Sessions1–3 per indication
GESYPrivate-pay (regenerative tier)
Overview

About this procedure

PRGF (Plasma Rich in Growth Factors) is the standardised, leukocyte-free autologous platelet protocol developed by BTI Biotechnology Institute (Vitoria-Gasteiz, Spain). Generic "PRP" varies in preparation, platelet concentration, leukocyte content, and activator. PRGF differs in protocol, characterisation, and regulatory file: a closed, single-step centrifugation that yields two plasma fractions (F1 at 1 to 1.5x platelet concentration, F2 at 2 to 3x and leukocyte-free), activated with calcium chloride immediately before infiltration.

In Cyprus, PRGF is administered using the Endoret® system, distributed exclusively by OrganoGEN. A small autologous blood draw is processed on-site, activated, and infiltrated at the target joint, tendon, or soft-tissue lesion. Typical clinic visit is under 60 minutes end-to-end. The technology has been used clinically since 1999, the first PRP-class biologic published for musculoskeletal indications.

Eligibility

Are you a candidate?

  • check_circleLikely yes: Mild-to-moderate knee osteoarthritis (Kellgren-Lawrence grade 1 to 3)
  • check_circleLikely yes: Mild-to-moderate hip or shoulder osteoarthritis
  • check_circleLikely yes: Chronic tendinopathy (rotator cuff, lateral epicondyle, patellar, achilles, plantar fascia)
  • check_circleLikely yes: Soft-tissue injury and post-surgical augmentation
  • check_circleLikely yes: Patients seeking a non-surgical regenerative option, or seeking to delay arthroplasty
  • cancelNot suitable: Active local or systemic infection
  • cancelNot suitable: Active malignancy at or near the target site
  • cancelNot suitable: Severe haematological disorder or coagulopathy
  • cancelNot suitable: End-stage osteoarthritis (Kellgren-Lawrence 4) where joint replacement is the appropriate option
  • cancelNot suitable: Patient-specific contraindications to autologous blood handling
GESY & Cost

GESY coverage & out-of-pocket cost

This is a private-pay procedure. Endoret® (PRGF) sits in the regenerative tier in Cyprus and is not covered by GESY. GESY covers standard orthopaedic surgical procedures and conventional injectables. Autologous biologics are private-pay. OrganoGEN provides clinic quotations on request. Request a quote.

Devices used

Devices used in this procedure

Device

Endoret® PRGF - Plasma Rich in Growth Factors

Regenerative Medicine · Plasma Rich in Growth Factors

chevron_right
Where it's offered in Cyprus

Find a clinic

GESY

Limassol

place Participating GESY-contracted hospitals

chevron_right
GESY

Nicosia

place Participating GESY-contracted hospitals

chevron_right
GESY

Larnaca

place Participating GESY-contracted hospitals

chevron_right
GESY

Paphos

place Participating GESY-contracted hospitals

chevron_right
GESY

Famagusta

place Participating GESY-contracted hospitals

chevron_right
FAQ

Patient questions

What is the difference between PRGF and PRP?
PRGF (Plasma Rich in Growth Factors) is the standardised, leukocyte-free autologous protocol developed by BTI Biotechnology Institute. Generic "PRP" varies in preparation, platelet concentration, leukocyte content, and activator. PRGF is prepared with a closed single-step centrifugation that yields two plasma fractions (F1 at 1 to 1.5x platelet concentration, F2 at 2 to 3x and leukocyte-free), activated with calcium chloride at the point of care. PRGF is classified as a pure, leukocyte-free P-PRP in the standard PRP taxonomy (Dohan Ehrenfest 2009, PubMed 19187989).
Is PRGF covered by GESY in Cyprus?
No. Endoret® (PRGF) is a private-pay regenerative procedure in Cyprus. GESY covers standard orthopaedic procedures and conventional injectables. Autologous biologics sit in the private tier.
What does the published evidence show?
The strongest evidence is in mild-to-moderate knee osteoarthritis and chronic rotator cuff tendinopathy. In a 176-patient multicentre double-blind randomised controlled trial, PRGF-Endoret produced a response rate 14.1 percentage points higher than hyaluronic acid at 24 weeks (Sánchez 2012, PubMed 22840987). In a 96-patient randomised trial, PRGF-Endoret was significantly superior to Durolane hyaluronic acid on WOMAC and Lequesne at 24 and 48 weeks (Vaquerizo 2013, PubMed 24075613). In a 79-patient double-blind trial in chronic rotator cuff tendinopathy, three biweekly PRGF injections were 22.1% superior to corticosteroid on UCLA at 6 months, sustained at 12 months (Vaquerizo 2023, PubMed 36183895). The 2024 ESSKA-ORBIT European consensus regards PRP as a valid first-line injectable option for non-operative management of knee osteoarthritis at Kellgren-Lawrence grades 1 to 3 (Laver et al. 2024).
How many sessions are needed?
Typically 1 to 3 sessions depending on indication and clinical response. The published knee osteoarthritis protocol uses 3 weekly injections per cycle (Sánchez 2012, Vaquerizo 2013). The rotator cuff tendinopathy protocol uses 3 biweekly injections (Vaquerizo 2023). A 90-patient trial in knee osteoarthritis found that two cycles improved stiffness and activities of daily living versus one cycle, without an additional reduction in pain (Vaquerizo 2018, PubMed 28526995).
Is PRGF safe? Are there side effects?
PRGF uses 100% autologous material, the patient's own blood, with no synthetic additives beyond the calcium chloride activator. Reported side effects in published trials are limited to mild local soreness at the injection site for 24 to 48 hours. The 2024 ESSKA-ORBIT consensus rated PRP as having a safer use profile than corticosteroid injection.
Is the Endoret® system regulated?
Yes. The Endoret® closed-technique system carries the European CE health certificate awarded by TÜV-SUD for application to musculoskeletal injuries and is manufactured under ISO 13485:2016 by BTI Biotechnology Institute, Vitoria-Gasteiz, Spain.
Where can I have PRGF injection done in Cyprus?
Through Endoret-trained clinicians in OrganoGEN's network. Contact us for the current list in Limassol, Nicosia, Larnaca, Paphos, and Famagusta.